Shelton Capital Management Has $14.37 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Shelton Capital Management trimmed its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 155,582 shares of the biopharmaceutical company’s stock after selling 3,867 shares during the period. Shelton Capital Management’s holdings in Gilead Sciences were worth $14,371,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. McAdam LLC boosted its stake in shares of Gilead Sciences by 16.7% during the 4th quarter. McAdam LLC now owns 25,372 shares of the biopharmaceutical company’s stock worth $2,344,000 after buying an additional 3,627 shares during the last quarter. Capital Investment Advisors LLC grew its stake in shares of Gilead Sciences by 2.6% in the fourth quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company’s stock valued at $35,793,000 after buying an additional 9,791 shares in the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its holdings in Gilead Sciences by 3.9% during the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 142,167 shares of the biopharmaceutical company’s stock worth $13,132,000 after buying an additional 5,382 shares during the last quarter. Global Financial Private Client LLC raised its position in Gilead Sciences by 1,222.0% during the fourth quarter. Global Financial Private Client LLC now owns 6,068 shares of the biopharmaceutical company’s stock worth $561,000 after acquiring an additional 5,609 shares in the last quarter. Finally, Exome Asset Management LLC acquired a new stake in Gilead Sciences in the third quarter valued at $4,192,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the sale, the chief financial officer now owns 129,873 shares of the company’s stock, valued at $11,863,898.55. This trade represents a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders have sold 302,785 shares of company stock worth $30,503,250 over the last ninety days. Insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Down 1.6 %

Shares of NASDAQ GILD opened at $105.52 on Tuesday. The company has a 50 day simple moving average of $107.50 and a 200 day simple moving average of $96.13. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $119.96. The firm has a market cap of $131.39 billion, a PE ratio of 285.19, a price-to-earnings-growth ratio of 0.71 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Investors of record on Friday, March 14th were paid a $0.79 dividend. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.99%. The ex-dividend date of this dividend was Friday, March 14th. Gilead Sciences’s payout ratio is currently 854.05%.

Analyst Ratings Changes

A number of brokerages have recently issued reports on GILD. Deutsche Bank Aktiengesellschaft raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and upped their target price for the company from $80.00 to $120.00 in a report on Tuesday, February 18th. Oppenheimer raised their price objective on Gilead Sciences from $115.00 to $132.00 and gave the company an “outperform” rating in a research report on Tuesday, March 4th. Royal Bank of Canada lifted their target price on Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a research note on Wednesday, February 12th. Cantor Fitzgerald restated a “neutral” rating and issued a $80.00 price target on shares of Gilead Sciences in a research note on Wednesday, December 11th. Finally, DZ Bank raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price objective for the company in a research report on Thursday, February 13th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $105.12.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.